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In the lower graph (Fig. 1C), we can observe an increase in ΔADC as 
dose increases, although the data are not relevant enough because of 
the few number of patients analyzed. 
Conclusions: ADC maps can be used not only for treatment 
assessment, but also for quantification of tumour response voxel by 
voxel. Even more, the joint use of MRI diffusion data and PET/CT can 
be useful for delimiting the hypoxic areas, due to glucose 
consumption enhancement by Pasteur effect. The main weakness of 
this method is the rigid registration process, and non rigid registration 
algorithms are needed for the registration of highly distorted images 
from diffusion studies. 
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Purpose/Objective: In radiotherapy (RT) of prostate cancer the key 
organs at risk (ORs) – the rectum and the bladder – display 
considerable motion, which may influence the dose/volume 
parameters predicting for morbidity. In this study we compare motion-
inclusive doses to planned doses for the rectum and bladder and 
explore their associations with prospectively recorded morbidity.  
Materials and Methods: The study included 38 prostate cancer 
patients treated with hypo-fractionated image-guided intensity-
modulated RT that had an average of nine repeat CT scans acquired 
during treatment. These scans were registered to the respective 
treatment planning CT (pCT) followed by a new dose calculation from 
which motion-inclusive dose distributions were derived. The pCT 
volumes, the treatment course averaged volumes as well as the 
planned and motion-inclusive doses were associated with acute and 
late morbidity (morbidity cut-off: ≥ Grade 2). 
Results: Acute rectal morbidity (observed in 29% of cases) was 
significantly associated with both smaller treatment course averaged 
rectal volumes (population median: 75 vs. 94 cm-3) and the motion-
inclusive volume receiving doses close to the prescription dose (2Gy-
equivalent dose of 76 Gy).  
Conclusions: Variation in rectum and bladder volumes leads to 
deviations between planned and delivered dose/volume parameters 
that should be accounted for to improve the ability to predict 
morbidity following RT.  
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Purpose/Objective: Biomarkers extracted from functional images may 
be subject to cross-institutional variations, and are thus in need of 
standardization. Pharmacokinetic parameters derived from dynamic 
contrast enhanced (DCE) MRI of cervical cancers have shown a 
predictive value in identifying patients at risk of relapse following 
radiotherapy. The aim of the current work was to compare 
pharmacokinetic parameters obtained from DCEMR images, acquired 
at different institutions, of patients with locally advanced cervical 
cancers. 
Materials and Methods: DCEMRI images from 2 centers have so far 
been collected. At center 1 (Oslo University Hospital), 78 patients 
have been included. Here, DCEMRI was performed using Magnevist 
(Gadopentetate Dimeglumine) as contrast agent and an FSPGR 
sequence with temporal resolution of 15 s and spatial resolution of 
0.8x0.8x5 mm at a 1.5T Signa Horizon LX scanner (GE Medical 
Systems). At center 2 (University Medical Center, Utrecht), 23 
patients have been included. In this case, DCEMRI was performed 
using Magnevist and a 3D FLASH sequence with 2.4 s temporal 
resolution and spatial resolution 0.9x0.9x3mm at a 1.5T Gyroscan NT 
Intera scanner (Philips Medical Systems). Pharmacokinetic analysis 
with the ‘Brix’ model was performed in an identical manner for the 
two cohorts. The model analysis of the dynamic series was done voxel 
by voxel in the tumors, providing maps of the ABrix (amplitude), kep 
and kel parameters. The median of a given parameter was extracted 
for each patient, in addition to a relative measure of tumor 
heterogeneity (difference between 66th and 33rd percentile, divided by 
the median). Cohort data for each center was compared using Mann-
Whitney tests. P-value<0.05 was considered statistically significant. 
Results: The cohort-based median values for center 1 versus center 2 
was 2.20 vs 3.41 (relative units), 1.59 vs 0.68 (min-1) and 0.076 vs 
0.080 (min-1) for ABrix, kep and kel, respectively. For the heterogeneity 
measure, values obtained were 0.40 vs 0.55, 0.54 vs 0.99 and 1.10 vs 
1.70, respectively. Non-significant differences were only found for 
median values of kel. 
Conclusions: Five out of six pharmacokinetic tumor parameters 
obtained from DCEMRI performed at the two different institutions 
were significantly different in this preliminary analysis, possibly 
pointing at differences in MR scanners and acquisition protocols. We 
aim at including patients from more institutions, at introducing the 
‘Tofts’ pharmacokinetic model and at using reference tissue for 
normalization. Furthermore, data are to be analyzed in a multivariate 
setting, accounting for variations in stage, tumor volume and other 
relevant clinical factors. 
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Purpose/Objective: Nowadays, quantitative 3D Ultrasound (US) Image 
Guided Radiotherapy (IGRT) systems are available which can assess 
absolute volumetric information on soft tissue. Acquiring daily US 
images is quick and imposes no extra radiation burden to the patient. 
For intramodality US systems only the reference CT (planning) image 
is available. Nevertheless, CT images for every treatment fraction 
would be useful, e.g. for dose recalculation, and assessing margins. To 
this end, deformable image registration (DIR) was applied to calculate 
the deformation field between reference and daily US images. This 
field was then applied to the reference CT.  
Materials and Methods: To validate the procedure a deformable 
phantom was developed, existing of a PMMA box filled with 
demineralized water, containing two balloons filled with either saline 
solution or sunflower oil with a variable volume. Four different 
configurations were imaged with CT as well as US. Deformation fields 
are computed between several pairs of US images and then applied to 
the corresponding CT of the first US of the pair (see figure). This 
reconstructed new, matching CT for the second US is then compared 
to the real corresponding CT of the second US using the sum of 
squared differences (SQD) metric. The deformation fields are 
calculated using an elastic registration algorithm (REGGUI; morphons). 
The SQD metric was limited to the area where US information was 
available.  
